Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21)

Key Dates: 
  • Open Date (Earliest Submission Date): December 11, 2015
  • Letter of Intent Due Date(s): Not Applicable
  • Application Due Date(s): January 11, 2016; January 11, 2017; and January 11, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): January 11, 2016; January 11, 2017; and January 11, 2018, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: March 2016; March 2017; March 2018
  • Advisory Council Review: May 2016; May 2017; May 2018
  • Earliest Start Date: July 2016; July 2017: July 2018
Purpose: 

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research on innate and adaptive immune responses induced by mycobacterial infection, Bacillus Calmette-Guérin vaccine (BCG), or other Mycobacterium tuberculosis (Mtb) vaccinations. Studies that include evaluation of immune responses by anatomical location in HIV-infected or uninfected individuals are of particular interest. A secondary objective of this FOA is development of new assays and technologies enabling comparison of mycobacterial-specific mucosal and systemic immunological pathways in HIV-infected or uninfected individuals that can be used to monitor immune responses in preclinical studies and vaccine trials to advance Mtb vaccine development.

Expiration Date: 
Friday, January 12, 2018
Announcement Number: 
PAR-15-360